Antiplatelet drugs are widely utilized in the setting of primary stroke prevention, secondary
stroke prevention, and neuroendovascular device-related stroke prevention. These …

There is considerable interindividual variability in the response to antiplatelet and
anticoagulant therapies, and this variation may be attributable to genetic variants. There has …

Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances,
primarily using the genome-wide association study approach, are transforming what we …

Genetic variations have been shown to influence drug metabolism, risk of adverse drug
events, and pharmacodynamic responses for many drugs routinely used to treat patients …

Genetics has given a real boost to personalized and precision medicine, providing data
used either for precise diagnostics, prediction of the course of illness, or for selecting therapy …

In patients undergoing percutaneous coronary intervention (PCI), the standard of care is
dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and …

Background: Previous reports have shown inadequate response to dual antiplatelet therapy
(DAPT) with aspirin and clopidogrel in 5-30% of patients undergoing percutaneous coronary …

Circulatory disease accounts for fifteen million deaths each year, of which stroke accounts
for four and a half million-with an estimated nine million stroke survivors annually. The …

Clopidogrel efficacy is influenced by genetic variation of cytochrome P450 (CYP) 2C19,
however, few studies have considered patients who have a stroke. We used electronic …

Background: Clopidogrel is frequently used in patients with ischemic stroke or transient
ischemic attack (TIA), but its efficacy is hampered by inter-individual variability, due to …